Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note released on Wednesday,Benzinga reports. Needham & Company LLC currently has a $9.00 price objective on the stock.

Other equities analysts have also recently issued reports about the company. Chardan Capital reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a report on Tuesday, May 6th. Oppenheimer dropped their price objective on Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.25.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $2.77 on Wednesday. The stock has a market capitalization of $99.69 million, a PE ratio of -1.41 and a beta of 0.01. The business has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $1.75. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $3.83.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). On average, equities analysts expect that Immuneering will post -1.86 EPS for the current year.

Insider Transactions at Immuneering

In other Immuneering news, Director Thomas J. Schall purchased 40,485 shares of the stock in a transaction dated Tuesday, June 17th. The stock was bought at an average price of $2.21 per share, with a total value of $89,471.85. Following the acquisition, the director now owns 43,385 shares of the company’s stock, valued at approximately $95,880.85. This represents a 1,396.03% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 22.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Immuneering

Institutional investors have recently modified their holdings of the business. Marshall Wace LLP acquired a new position in shares of Immuneering during the 4th quarter worth $47,000. Two Sigma Investments LP raised its holdings in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after buying an additional 10,126 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Immuneering by 33.7% during the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock worth $157,000 after buying an additional 18,000 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Immuneering during the 4th quarter worth $390,000. Finally, Bridgeway Capital Management LLC raised its holdings in shares of Immuneering by 77.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock worth $113,000 after buying an additional 22,400 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.